> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Artivion Revenue Grows 9% On Reported And Currency-Neutral Bases — Adjusted Profit Falls
- URL: https://www.bullished.co/artivion-revenue-grows-9-on-reported-and-currency-neutral-bases-adjusted-profit-falls-e82c4243/
- Published: 2026-11-06T15:21:03.000Z
- Updated: 2026-11-06T15:21:03.000Z
- Description: The cardiac-surgery company narrowed its full-year outlook as it prepares to launch NEXUS in the U.S. in January 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, AORT, Industry: Healthcare

[Artivion](https://www.bullished.co/tag/aort/), which supplies devices and implantable human tissues for cardiac and vascular surgery, grew third-quarter revenue 9% on both reported and currency-neutral bases to [$123.8 million](https://www.prnewswire.com/news-releases/artivion-reports-third-quarter-2026-financial-results-302931299.html?ref=bullished.co), but adjusted profit fell to $3.8 million from $7.9 million a year earlier. The company reported the results Thursday and narrowed its full-year revenue and adjusted earnings outlook.

## Higher Sales, Less Profit

AORT shares plunged about 13% to $21.96 in Friday trading. Quarterly revenue was [$113.4 million](https://www.prnewswire.com/news-releases/artivion-reports-third-quarter-2026-financial-results-302931299.html?ref=bullished.co) a year earlier, while adjusted diluted earnings fell to $0.08 a share from $0.16.

Under standard accounting, Artivion swung to a $7.9 million loss, or $0.16 per diluted share, from a $6.5 million profit, or $0.13 per share. Adjusted earnings before interest, taxes, depreciation and amortization declined 8% to $22.5 million from $24.6 million.

Costs absorbed much of the sales increase: gross profit reached $75.977 million versus $74.395 million, while operating expenses rose to $73.030 million from $65.359 million. Interest expense increased to $8.518 million from $6.119 million; the year-earlier quarter also included a $3.5 million gain from selling nonfinancial assets.

Cash generation weakened, too. Third-quarter operating activities used $4.556 million, compared with generating $22.262 million a year earlier. Capital spending reached $13.013 million versus $4.609 million, leaving free cash flow negative at $17.569 million, against positive $17.653 million.

## A Narrower 2026 Range

Artivion's [revenue outlook](https://www.sec.gov/Archives/edgar/data/0000784199/000162828026071029/aort-2026x8k093026ex991.htm?ref=bullished.co) now spans $484 million to $492 million, replacing $480 million to $496 million. The new range implies adjusted currency-neutral growth of 8% to 10%, versus 7% to 11% previously: the company lifted the floor and lowered the ceiling rather than cutting the entire range.

The same pattern applies to adjusted earnings before interest, taxes, depreciation and amortization, now forecast at [$93 million](https://www.theglobeandmail.com/investing/markets/markets-news/motley/8692111/artivion-aort-q3-2026-earnings-call-transcript/?ref=bullished.co) to $98 million instead of $92 million to $99 million. That includes approximately $8 million of expenses associated with Endospan, whose acquisition closed in May 2026.

The revenue growth comparison uses adjusted 2025 sales that exclude a $2.3 million reserve for estimated repayments to the Italian government. Management continues to expect currency movements to add approximately one percentage point to full-year growth.

## On-X Growth And NEXUS Preparations

On-X mechanical heart valve sales rose 13% from a year earlier excluding currency movements, while aortic stent-graft sales rose 12% on that basis. Surgical sealants and tissue-preservation services were flat on a currency-neutral basis.

Those businesses form Artivion's product lineup alongside implantable cardiac and vascular tissues. Its customers are principally cardiac and vascular surgeons treating aortic disease, and it sells products in more than 100 countries.

Pat Mackin, Artivion's chairman, president and chief executive officer, said U.S. AMDS implants increased from the second quarter. He also said investments in the Austin manufacturing facility improved On-X supply and that enrollment in the ARTIZEN clinical trial for ARCEVO LSA remains on schedule.

Mackin said preparations for the January 2027 U.S. commercial launch of NEXUS “[are progressing well](https://www.sec.gov/Archives/edgar/data/0000784199/000162828026071029/aort-2026x8k093026ex991.htm?ref=bullished.co).” With recent U.S. approvals for AMDS and NEXUS and the ongoing ARCEVO LSA trial, he believes Artivion is on track to offer a comprehensive aortic-arch portfolio addressing an approximately $330 million annual U.S. market opportunity.

Artivion plans its first NEXUS surgeon-training event in December, ahead of the planned January 2027 U.S. launch.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ARTIVION, INC. (AORT)](https://www.sec.gov/Archives/edgar/data/0000784199/000162828026071029/aort-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit aort-2026x8k093026ex991.htm — ARTIVION, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000784199/000162828026071029/aort-2026x8k093026ex991.htm?ref=bullished.co) — SEC EDGAR
- [Artivion (AORT) Q3 2026 Earnings Call Transcript - The Globe and Mail](https://www.theglobeandmail.com/investing/markets/markets-news/motley/8692111/artivion-aort-q3-2026-earnings-call-transcript/?ref=bullished.co) — theglobeandmail.com
- [Artivion Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/artivion-reports-third-quarter-2026-financial-results-302931299.html?ref=bullished.co) — prnewswire.com

### More on Artivion

- [Artivion Says $100,000 Upfront Cost Is Stalling AMDS Starter-Set Orders Even As Implants Rise](https://www.bullished.co/artivion-says-100-000-upfront-cost-is-stalling-amds-starter-set-orders-even-as-implants-63ec5414/)

[All Artivion (AORT) coverage →](https://www.bullished.co/tag/aort/)